First AD

Second AD

PRECISION trial

Video content above is prompted by the following:

The PRECISION trial was a phase 3, multicenter, randomized study of aprocitentan, a dual ERA, in patients with a systolic blood pressure of 140 mm Hg or higher despite taking 3 antihypertensive drugs, including a diuretic.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Video Series

Advancing Hypertension Management: Unmet Needs, Endothelial Dysfunction, and CKD Therapies

Difficult-to-treat hypertension is a condition where blood pressure remains uncontrolled despite the use of three or more antihypertensive medications, including a diuretic. This condition is distinct from resistant hypertension, which is more common and involves blood pressure that is not controlled with three medications but may not include a diuretic. Difficult-to-treat hypertension is less frequent, affecting a smaller subset of patients with high blood pressure. It often requires a more comprehensive approach, including lifestyle modifications and potential secondary causes evaluation, to achieve optimal management.

Panelists discuss how the PRECISION trial evaluated aprocitentan, a dual endothelin receptor antagonist (ERA), in patients with resistant hypertension taking 3 antihypertensive medications including a diuretic.